Reply
M. Eric Gershwin, Patrick S.C. Leung, William M. Ridgway, Ross L. Coppel, Aftab A. Ansari – 12 January 2013
Antimitochondrial antibodies may be insufficiently specific to define primary biliary cirrhosis‐like disease in mouse models
Simon Hohenester, Ulrich Beuers, Juan F. Medina, Ronald P. Oude Elferink – 12 January 2013
The role of biopsy of the nontumorous liver parenchyma in patients considered for partial resection of small hepatocellular carcinoma
David Fuks, Francois Durand, Jacques Belghiti – 12 January 2013
αB‐crystallin complexes with 14‐3‐3ζ to induce epithelial‐mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma
Xiao‐Yong Huang, Ai‐Wu Ke, Guo‐Ming Shi, Xin Zhang, Chi Zhang, Ying‐Hong Shi, Xiao‐Ying Wang, Zhen‐Bin Ding, Yong‐Sheng Xiao, Jun Yan, Shuang‐Jian Qiu, Jia Fan, Jian Zhou – 12 January 2013 – The overall survival of patients with hepatocellular carcinoma (HCC) remains poor, and the molecular pathogenesis remains incompletely defined in HCC. Here we report that increased expression of αB‐Crystallin in human HCC predicts poor survival and disease recurrence after surgery.
Reply:
Sasan Roayaie, Josep Llovet, Myron Schwartz, Vincenzo Mazzaferro – 12 January 2013
C‐reactive protein, a prognostic marker in hepatocellular carcinoma
Jean‐François Dufour – 12 January 2013
Genome‐wide microRNA and messenger RNA profiling in rodent liver development implicates mir302b and mir20a in repressing transforming growth factor‐beta signaling
Wei Wei, Juan Hou, Olivia Alder, Xin Ye, Sam Lee, Rebecca Cullum, Andy Chu, Yongjun Zhao, Stephanie M. Warner, Darryl A. Knight, Decheng Yang, Steven J.M. Jones, Marco A. Marra, Pamela A. Hoodless – 12 January 2013 – MicroRNAs (miRNAs) are recently discovered small RNA molecules that regulate developmental processes, such as proliferation, differentiation, and apoptosis; however, the identity of miRNAs and their functions during liver development are largely unknown.
Activation of mammalian target of rapamycin complex 1 (mTORC1) and Raf/Pyk2 by growth factor‐mediated Eph receptor 2 (EphA2) is required for cholangiocarcinoma growth and metastasis
Xiang‐Dan Cui, Mi‐Jin Lee, Jong‐Hyun Kim, Pei‐Pei Hao, Lan Liu, Goung‐Ran Yu, Dae‐Ghon Kim – 11 January 2013 – Eph receptor 2 (EphA2) overexpression is frequently accompanied by the loss of its cognate ligand during tumor progression. However, the molecular mechanism of this ligand‐independent promotion of tumor by EphA2 remains unclear in highly malignant and fatal cholangiocarcinoma (CC). We examined the biological role of EphA2 in tumor growth and metastasis in CC tissues and cells according to the degree of differentiation and we explored the downstream signaling pathways of EphA2.
Improvement of neurocognitive function in responders to an antiviral therapy for chronic hepatitis C
Michael R. Kraus, Arne Schäfer, Gerlinde Teuber, Heiner Porst, Kathrin Sprinzl, Sven Wollschläger, Christian Keicher, Michael Scheurlen – 8 January 2013 – Earlier studies have suggested neurocognitive impairment in patients with chronic hepatitis C virus (HCV) infection even before liver cirrhosis has developed. Since these deficits might be reversible after successful antiviral therapy, we analyzed the long‐term course of neurocognitive parameters in HCV patients with and without successful virus elimination by an interferon‐based antiviral treatment.
Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models
Stephanie Coulon, Vanessa Legry, Femke Heindryckx, Christophe Van Steenkiste, Christophe Casteleyn, Kim Olievier, Louis Libbrecht, Peter Carmeliet, Bart Jonckx, Jean‐Marie Stassen, Hans Van Vlierberghe, Isabelle Leclercq, Isabelle Colle, Anja Geerts – 8 January 2013 – The pathophysiology of nonalcoholic steatohepatitis (NASH) should be approached as a multifactorial process. In several stages of NASH, a link between disease progression and hepatic microvasculature changes can be made.